Encoded Therapeutics Inc. closed on a $104 million series C financing round, bringing the precision gene therapy company into a narrow field dominated by technological limitations and only a handful of approved products. Read More
Recent bad phase IIb news from Inflarx NV with IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody in the moderate to severe skin disease hidradenitis suppurativa (HS), also dinged shares of Chemocentryx Inc., which has small-molecule avacopan targeting the C5a receptor in a registration-grade phase II study targeting the same indication – but the story's hardly over in HS or vasculitis. Read More
HONG KONG – Two Korean biotech companies, Genexine Inc. and Toolgen Inc., have agreed to merge into a single entity named Toolgenexine Inc., in order to develop novel immunotherapy drugs with gene editing technology. Read More
HONG KONG – With operations in the U.S, the Netherlands and China, Shanghai-based biopharma firm Harbour Biomed Therapeutics Ltd. inked a 10-year pact with Erasmus MC from the University Medical Center Rotterdam to grow its footprint in Europe. Both sides will develop biotherapeutics to treat cancer and immunological diseases. Read More
Minovia Therapeutics Ltd., an Israeli company running the first ever cell therapy trial to treat a mitochondrial disease, has dosed the first participant in a phase I/II study of a treatment for the rare pediatric condition Pearson syndrome. A second patient will be dosed in three weeks. Five of the seven patients that will ultimately participate in the trial have already been recruited, fueling hope that the study will be completed by year-end or earlier. Read More
Amylyx Pharmaceuticals Inc., of Cambridge, Mass., appointed Patrick Yeramian chief medical officer, Margaret Olinger chief commercial officer and Tom Holmes global head, supply chain. Read More
Pantheryx Inc., of Boulder, Colo., completed $50 million in new financing with Perceptive Advisors. Proceeds will be used to accelerate development of medical foods and biologics, as well as support expansion of its existing nutritionals. Read More
Xenetic Biosciences Inc., of Framingham, Mass., said on June 25 it effected a 1-for-12 reverse stock split of its issued and outstanding common shares. The company's common stock continues to trade on Nasdaq on a split-adjusted basis under the ticker XBIO, closing Wednesday at $8.30 for a loss of 86 cents. Read More
